Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Hypertension Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Association of Angiotensin Converting Enzyme Phenotypes and Polymorphisms with Clinical Outcomes in SARS-CoV2 Patients with Hypertension in an Urban Emergency Department

Abstract

Introduction

The role of Angiotensin-converting enzyme (ACE and ACE2) phenotypes and polymorphisms in modulating severe acute respiratory syndrome coronavirus (SARS-CoV2) infection in hypertensive patients remains unclear. Our objective was to determine the distribution of ACE and ACE2 receptor phenotypes by patient demographics and correlate ACE and ACE2 levels of activity with SARS-CoV-2 outcomes.

Methods

Hypertensive patients treated for SARS-CoV-2 at an urban emergency department (ED) were prospectively enrolled in a cohort study between August 2020 and April 2021. Blood samples were collected during ED visits or hospitalization. Outcome measures including hospitalization, intensive care unit (ICU) admission, and 30-day mortality were obtained from electronic health records. Multivariable logistic regression was used.

Results

Of the 150 patients enrolled, 60% were Black, 32% Hispanic/Latinx, 4% Non-Hispanic Whites, and 4% others. The mean age was 59 (+/-14) years. The rate of hospitalization was high (86%) and Hispanic/Latinx had a higher likelihood of ICU admission. Patients harboring the rs2285666 genotype TT, AA, and GC alleles were more likely to be admitted to ICU, and those with TT and AA had higher mortality. The ACE level was a significant predictor of hospitalization with a protective effect in both unadjusted and adjusted results. Hispanics/Latinx had a four times higher likelihood of ICU admission compared to all others, and age was significantly associated with 30-day mortality.

Conclusion

Our results show that even after adjusting for age, race, and sex, ACE levels remained a predictor of hospitalization. ACE/ACE2 phenotypes and genotypes potentially play an important role in disease progression in SARS-CoV-2 patients.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chyr/10.2174/0115734021315730240919062555
2024-10-15
2024-11-26

  • From This Site

    /content/journals/chyr/10.2174/0115734021315730240919062555
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sug S. Fryar C.D. Carroll M.D. Hypertension Prevalence and Control Among Adults: United States, 2011-2014. NCHS Data Brief 2015 220 1 8
    [Google Scholar]
  2. High Blood Pressure Facts. 2024 Available from: https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html
  3. Aggarwal R. Chiu N. Wadhera R.K. Moran A.E. Raber I. Shen C. Yeh R.W. Kazi D.S. Racial/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the United States, 2013 to 2018. Hypertension 2021 78 6 1719 1726 10.1161/HYPERTENSIONAHA.121.17570 34365809
    [Google Scholar]
  4. Alcendor D.J. Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US. J. Clin. Med. 2020 9 8 2442 10.3390/jcm9082442 32751633
    [Google Scholar]
  5. Tai D.B.G. Shah A. Doubeni C.A. Sia I.G. Wieland M.L. The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States. Clin. Infect. Dis. 2021 72 4 703 706 10.1093/cid/ciaa815 32562416
    [Google Scholar]
  6. Latest Data. Available from: https://www.chicago.gov/city/en/sites/covid-19/home/covid-dashboard.html
  7. Soler M.J. Barrios C. Oliva R. Batlle D. Pharmacologic modulation of ACE2 expression. Curr. Hypertens. Rep. 2008 10 5 410 414 10.1007/s11906‑008‑0076‑0 18775121
    [Google Scholar]
  8. Shah H. Khan M.S.H. Dhurandhar N.V. Hegde V. The triumvirate: Why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 2021 58 7 831 843 10.1007/s00592‑020‑01636‑z 33587177
    [Google Scholar]
  9. Bosso M. Thanaraj T.A. Abu-Farha M. Alanbaei M. Abubaker J. Al-Mulla F. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol. Ther. Methods Clin. Dev. 2020 18 321 327 10.1016/j.omtm.2020.06.017 32665962
    [Google Scholar]
  10. Liu Y. Yang Y. Zhang C. Huang F. Wang F. Yuan J. Wang Z. Li J. Li J. Feng C. Zhang Z. Wang L. Peng L. Chen L. Qin Y. Zhao D. Tan S. Yin L. Xu J. Zhou C. Jiang C. Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 2020 63 3 364 374 10.1007/s11427‑020‑1643‑8 32048163
    [Google Scholar]
  11. Suzuki Y. Ruiz-Ortega M. Lorenzo O. Ruperez M. Esteban V. Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003 35 6 881 900 10.1016/S1357‑2725(02)00271‑6 12676174
    [Google Scholar]
  12. Imai Y. Kuba K. Penninger J.M. The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol. 2008 93 5 543 548 10.1113/expphysiol.2007.040048 18448662
    [Google Scholar]
  13. Wu Z. Hu R. Zhang C. Ren W. Yu A. Zhou X. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit. Care 2020 24 1 290 10.1186/s13054‑020‑03015‑0 32503680
    [Google Scholar]
  14. Mitchell P.D. Buckley C. Subramaniam A. Crowther S. Donnelly S.C. Elevated serum ACE levels in patients with post-acute COVID-19 syndrome. QJM 2022 115 10 651 652 10.1093/qjmed/hcac119 35588264
    [Google Scholar]
  15. Gu J. Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol. 2007 170 4 1136 1147 10.2353/ajpath.2007.061088 17392154
    [Google Scholar]
  16. Zhao Y. Zhao Z. Wang Y. Zhou Y. Ma Y. Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med. 2020 202 5 756 759 10.1164/rccm.202001‑0179LE 32663409
    [Google Scholar]
  17. Singh U. Wurtele E.S. Differential expression of COVID-19-related genes in European Americans and African Americans. bioRxiv 2020.06.09.143271 10.1101/2020.06.09.143271
    [Google Scholar]
  18. Rigat B. Hubert C. Alhenc-Gelas F. Cambien F. Corvol P. Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 1990 86 4 1343 1346 10.1172/JCI114844 1976655
    [Google Scholar]
  19. Rigat B. Hubert C. Corvol P. Soubrier R. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 1992 20 6 1433 1433 10.1093/nar/20.6.1433‑a 1313972
    [Google Scholar]
  20. Han C. Han X.K. Liu F.C. Huang J.F. Ethnic differences in the association between angiotensin‐converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta‐analysis. Chronic Dis. Transl. Med. 2017 3 4 230 241 10.1016/j.cdtm.2017.07.002 29354806
    [Google Scholar]
  21. Sarangarajan R. Winn R. Kiebish M.A. Bountra C. Granger E. Narain N.R. Ethnic prevalence of angiotensin-converting enzyme deletion (D) polymorphism and COVID-19 risk: Rationale for use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. J. Racial Ethn. Health Disparities 2021 8 4 973 980 10.1007/s40615‑020‑00853‑0 32901433
    [Google Scholar]
  22. Keikha M. Karbalaei M. Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis. Microb. Pathog. 2022 172 105781 10.1016/j.micpath.2022.105781 36116608
    [Google Scholar]
  23. Avanoglu Guler A. Tombul N. Aysert Yıldız P. Özger H.S. Hızel K. Gulbahar O. Tufan A. Erbaş G. Aygencel G. Guzel Tunçcan O. Dizbay M. Öztürk M.A. The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease. Scand. J. Clin. Lab. Invest. 2021 81 2 160 165 10.1080/00365513.2021.1871641 33474994
    [Google Scholar]
  24. Zhu Z. Cai T. Fan L. Lou K. Hua X. Huang Z. Gao G. The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019. BMC Infect. Dis. 2020 20 1 883 10.1186/s12879‑020‑05619‑x 33238910
    [Google Scholar]
  25. Ghanbari H. Dehghani A. Feizi A. Amirkhani A. Pourazizi M. Serum level of the angiotensin-converting enzyme in patients with idiopathic acute optic neuritis: A case-control study. Scientifica (Cairo) 2020 2020 1 5 10.1155/2020/4867420 32318310
    [Google Scholar]
  26. Kahkouee S. Samadi K. Alai A. Abedini A. Rezaiian L. Serum ACE level in sarcoidosis patients with typical and atypical HRCT manifestation. Pol. Przegl. Radiol. Med. Nukl. 2016 81 458 461 10.12659/PJR.897708 27733890
    [Google Scholar]
  27. Rice G.I. Jones A.L. Grant P.J. Carter A.M. Turner A.J. Hooper N.M. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006 48 5 914 920 10.1161/01.HYP.0000244543.91937.79 17000927
    [Google Scholar]
  28. Pan M. Vasbinder A. Anderson E. Catalan T. Shadid H.R. Berlin H. Padalia K. O’Hayer P. Meloche C. Azam T.U. Khaleel I. Michaud E. Blakely P. Bitar A. Huang Y. Zhao L. Pop-Busui R. Loosen S.H. Chalkias A. Tacke F. Giamarellos-Bourboulis E.J. Reiser J. Eugen-Olsen J. Hayek S.S. Angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, and outcomes in patients hospitalized for COVID‐19. J. Am. Heart Assoc. 2021 10 24 e023535 10.1161/JAHA.121.023535 34889102
    [Google Scholar]
  29. Molnar M.Z. Kalantar-Zadeh K. Lott E.H. Lu J.L. Malakauskas S.M. Ma J.Z. Quarles D.L. Kovesdy C.P. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J. Am. Coll. Cardiol. 2014 63 7 650 658 10.1016/j.jacc.2013.10.050 24269363
    [Google Scholar]
  30. Fliser D. Buchholz K. Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004 110 9 1103 1107 10.1161/01.CIR.0000140265.21608.8E 15313950
    [Google Scholar]
/content/journals/chyr/10.2174/0115734021315730240919062555
Loading
Association of Angiotensin Converting Enzyme Phenotypes and Polymorphisms with Clinical Outcomes in SARS-CoV2 Patients with Hypertension in an Urban Emergency Department
Bentham Science Publishers ; https://doi.org/10.2174/0115734021315730240919062555
/content/journals/chyr/10.2174/0115734021315730240919062555
/content/journals/chyr/10.2174/0115734021315730240919062555
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: emergency department ; COVID-19 ; ACE ; hypertension ; hospitalization ; ACE2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test